ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,304.72
0.70%
Dow Jones
39,069.59
0.01%
US Dollar vs MXN
16.6998
0.00%
Brent Oil
81.965
0.00%
Bitcoin
68,756.59
0.34%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Karyopharm Therapeutics Inc (KPTI)

  7. Karyopharm Therapeutics Inc (KPTI) Noticias

KPTI

Karyopharm Therapeutics (KPTI)

Karyopharm Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:KPTI
FechaHoraFuenteTítuloSímboloCompañía
23/05/202415:30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KPTIKaryopharm Therapeutics Inc
14/05/202415:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202415:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202415:05PR Newswire (US)Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202406:30PR Newswire (US)Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202406:30PR Newswire (US)Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029NASDAQ:KPTIKaryopharm Therapeutics Inc
07/05/202415:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
02/05/202415:30PR Newswire (US)Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
01/05/202415:05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
24/04/202415:01PR Newswire (US)Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual MeetingNASDAQ:KPTIKaryopharm Therapeutics Inc
06/03/202415:05PR Newswire (US)Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma ConferencesNASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202406:43Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202406:30PR Newswire (US)Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
22/02/202406:00PR Newswire (US)Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
14/02/202409:33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KPTIKaryopharm Therapeutics Inc
08/01/202407:30PR Newswire (US)Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 ObjectivesNASDAQ:KPTIKaryopharm Therapeutics Inc
03/01/202406:00PR Newswire (US)Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
10/12/202319:15PR Newswire (US)Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)NASDAQ:KPTIKaryopharm Therapeutics Inc
08/11/202315:05PR Newswire (US)Karyopharm to Participate at Upcoming Investor ConferencesNASDAQ:KPTIKaryopharm Therapeutics Inc
06/11/202306:00PR Newswire (US)Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO StudyNASDAQ:KPTIKaryopharm Therapeutics Inc
02/11/202308:20PR Newswire (US)Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)NASDAQ:KPTIKaryopharm Therapeutics Inc
02/11/202306:30PR Newswire (US)Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
30/10/202307:00PR Newswire (US)Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple MyelomaNASDAQ:KPTIKaryopharm Therapeutics Inc
26/10/202306:00PR Newswire (US)Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023NASDAQ:KPTIKaryopharm Therapeutics Inc
26/09/202306:00PR Newswire (US)Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual MeetingsNASDAQ:KPTIKaryopharm Therapeutics Inc
01/09/202307:17Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
01/09/202307:00PR Newswire (US)Karyopharm Appoints Zhen Su, MD, MBA to its Board of DirectorsNASDAQ:KPTIKaryopharm Therapeutics Inc
02/08/202307:59Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KPTIKaryopharm Therapeutics Inc
02/08/202306:30PR Newswire (US)Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
26/07/202306:00PR Newswire (US)Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023NASDAQ:KPTIKaryopharm Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KPTI

Su Consulta Reciente

NYSE
XOM
Exxon Mobil
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USI
USTECH100
US Tech 100
NYSE
VZ
Verizon Communications
NASDAQ
MSFT
Microsoft
CCOM
OILBRENT
Brent Oil
COIN
ETHUSD
Ethereum
AMEX
XLE
Energy Select Sector SPDR
NYSE
MRK
Merck
CCOM
US500
US 500
AMEX
XLF
Financial Select Sector
USOTC
DTEGY
Deutsche Telekom (QX)
COIN
BTCUSD
Bitcoin
NASDAQ
GOOGL
Alphabet
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados